Dr Rupali Paranjape, an experienced regulatory and compliance consultant and author of Blue Ocean of Compliance shares insights on her book in an interview with Thomas C Thottathil, Editor, www.indianpharmapost.com
The new lab is a testament to the Pondicherry Institute of Medical Sciences (PIMS)’s long-held values and traditions of striving for excellence and embracing newer innovations in order to deliver the best standard of training for their students
‘Infinite Care’ comprises two key pillars - Sparsh Sankalpa and Sparsh Sukshema
Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
This cost-effective tool will be of immense benefit to other high burden countries as well.
The curriculum has been curated for General Physicians working in Clinikk
Tirzepatide is primarily indicated for the treatment of T2D and is expected to receive its decision from the FDA in Q2 2022
The new hospital is expected to open by March'24
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
Subscribe To Our Newsletter & Stay Updated
